TF and lung cancer: Finally, the radical signal-to-noise enrichment in MRD-EDGESNV enables plasma-only (non tumor-informed) disease monitoring in advanced melanoma and lung cancer, yielding clinically informative TF monitoring for patients on immune checkpoint inhibition (ICI).